UBS Group
WHWK

UBS Group’s Whitehawk Therapeutics WHWK Stock Holding History

UBS Group’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.5K Sell
11,438
-18,406
-62% -$57.6K ﹤0.01% 7525
2025
Q4 		$72.2K Buy
29,844
+24,151
+424% +$55.4K ﹤0.01% 7054
2025
Q3 		$10.8K Sell
5,693
-2,980
-34% -$5.48K ﹤0.01% 8517
2025
Q2 		$16.2K Sell
8,673
-26,894
-76% -$46.8K ﹤0.01% 8578
2025
Q1 		$63.3K Sell
35,567
-23,607
-40% -$61.6K ﹤0.01% 7398
2024
Q4 		$187K Buy
59,174
+8,467
+17% +$19.2K ﹤0.01% 6489
2024
Q3 		$104K Sell
50,707
-19,658
-28% -$31.8K ﹤0.01% 6324
2024
Q2 		$103K Buy
70,365
+49,654
+240% +$92K ﹤0.01% 6141
2024
Q1 		$48.5K Buy
20,711
+2,951
+17% +$5.69K ﹤0.01% 6525
2023
Q4 		$35.9K Buy
17,760
+8,634
+95% +$36.2K ﹤0.01% 6741
2023
Q3 		$44.2K Sell
9,126
-139
-2% -$808 ﹤0.01% 6367
2023
Q2 		$63.4K Buy
9,265
+2,841
+44% +$22.1K ﹤0.01% 6338
2023
Q1 		$46.5K Buy
6,424
+1,399
+28% +$14.9K ﹤0.01% 6508
2022
Q4 		$64.5K Buy
+5,025
New +$65.6K ﹤0.01% 6528
2022
Q3 		– Sell
-16,434
Closed -$202K – 11061
2022
Q2 		$202K Sell
16,434
-40,250
-71% -$598K ﹤0.01% 4901
2022
Q1 		$961K Buy
56,684
+32,590
+135% +$625K ﹤0.01% 4140
2021
Q4 		$581K Buy
24,094
+23,854
+9,939% +$599K ﹤0.01% 4847
2021
Q3 		$7K Buy
240
+227
+1,746% +$6.92K ﹤0.01% 8340
2021
Q2 		$0 Sell
13
-198
-94% -$4.52K ﹤0.01% 9916
2021
Q1 		$4K Sell
211
-1,243
-85% -$28.6K ﹤0.01% 8440
2020
Q4 		$21K Buy
1,454
+1,441
+11,085% +$30.8K ﹤0.01% 6923
2020
Q3 		$0 Hold
13
– – ﹤0.01% 8491
2020
Q2 		$0 Sell
13
-1,079
-99% -$14.1K ﹤0.01% 8438
2020
Q1 		$9K Buy
1,092
+823
+306% +$7.59K ﹤0.01% 7026
2019
Q4 		$2K Sell
269
-894
-77% -$7.45K ﹤0.01% 7861
2019
Q3 		$12K Buy
1,163
+219
+23% +$2.43K ﹤0.01% 7067
2019
Q2 		$13K Buy
944
+561
+146% +$8.51K ﹤0.01% 6911
2019
Q1 		$5K Buy
383
+200
+109% +$8.6K ﹤0.01% 7194
2018
Q4 		$5K Buy
183
+118
+182% +$3.76K ﹤0.01% 7569
2018
Q3 		$3K Buy
+65
New +$3.65K ﹤0.01% 7678

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

UBS Group's WHWK Position: Q1 2026 in Review

UBS Group reduced its Whitehawk Therapeutics (WHWK) stake by 62% in Q1 2026, selling an estimated $57.6K and leaving 11,438 shares worth $39.5K. The position accounts for ﹤0.01% of the portfolio, ranked #7525.

UBS Group first reported a position in WHWK in Q3 2018 and has held it in 30 quarters since. The position peaked at $961K in Q1 2022. 62 funds tracked by Wall St. Rank hold WHWK as of Q1 2026.

  • UBS Group held 11,438 shares of Whitehawk Therapeutics worth $39.5K as of Q1 2026.
  • UBS Group sold 18,406 Whitehawk Therapeutics shares in Q1 2026, an estimated $57.6K.
  • Whitehawk Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7525 holding.
  • UBS Group first reported a position in Whitehawk Therapeutics in Q3 2018 and has held it in 30 quarters since.
  • UBS Group's Whitehawk Therapeutics position peaked at $961K in Q1 2022.
  • 62 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.